Screening and Identification of New Potential Targets against *Mycobacterium tuberculosis*

Guilherme Felipe dos Santos Fernandes, Chung Man Chin and Jean Leandro dos Santos*

Faculdade de Ciências Farmacêuticas, UNESP – Univ Estadual Paulista, Araraquara. Rodovia Araraquara-Jaú Km 01 s/n, 14801-902, Araraquara, São Paulo, Brazil

**Editorial**

Tuberculosis (TB), which is caused mainly by *Mycobacterium tuberculosis* (MTB), is still a serious concern worldwide due to rising number of drug resistance cases and HIV-TB co-infection [1]. In 2013, over 9 million new cases were diagnosed and around 1.5 million deaths were caused by MTB infection. In 2010, it was estimated that 4% of new TB cases were multidrug-resistant TB (MDR-TB) [2]. The increased number of MDR-TB and extensively drug-resistant TB (XDR-TB), adverse effects of available drugs and long-term therapy justify the search for new safe and effective antitubercular drugs.

Since rifampicin discovery in the sixties, few advances were reached in anti-TB therapy. Only in 2012, the United States Food and Drug Administration (FDA) approved the drug bedaquiline to treat MDR-TB. Despite this scary scenario, in the last years the number of drug candidates to treat resistant TB has increased and compounds such as OPC-67683, SQ-109, PA-824, LL-3858 are currently under evaluation [3]. The success to identify new drug candidates is related in part to screening campaigns performed by both academia and pharmaceutical companies. Target-based assays and whole-cell screening can be used during screening for antitubercular compounds. The target-based strategy is a powerful tool that allows identifying the mode of action of compounds. This strategy also contributes to optimize the antimycobacterial activity of prototypes. However, the main limitation of this strategy includes the need of target validation since some biochemical pathway in MTB can be not essential in the disease pathogenesis [4]. In addition, activation of alternative pathways and efflux mechanisms present in the mycobacteria can decrease the efficacy of this strategy. On the other hand, whole-cell screening has shown to be a promising strategy to identify new antitubercular drug candidates. Bedaquiline and compounds such as NITD-304 and NITD-349 were discovered using this strategy. This phenotypic assay does not require knowledge about the mode of action allowing the identification of new chemical entities able to inhibit new targets or pathways in MTB. Furthermore, this strategy is useful for prodrg’s identification and it also allows characterizing the selectivity of the compounds against MTB. Since there is not information about the target, the optimization of compounds using this strategy can be a hard task.

Nowadays, the combination of both strategies seems to be more efficient to identify new chemical structures with different mechanism of actions. In general, anti-mycobacterial activity is first identified through phenotypic assay. After, techniques such as DNA microarrays, gene knockdown and characterization of mutated genes of compound-resistant mutants contribute to the identification of probable targets. The expression, purification and crystallization of these targets allow optimizing the activity of those compounds in order to identify a possible drug candidate [5].

Several potential targets have been identified in MTB using combined strategies. Some examples include: a) DNA gyrase (gyrB subunit) and topoisomerase 1 – both involved in DNA synthesis; b) MbtA – involved in the iron metabolism of MTB; c) cytochrome b subunit (QcrB) and type II NADH dehydrogenase – involved in energy generation; d) decaprenylphosphoryl-β-D-ribose 20-epimerase (DprE), fatty acid synthases (FASs) and polyketide synthases (PKSs) involved in cell wall biosynthesis; e) Mycobacterial membrane protein large (MmpL) – involved in transport of ions and organic compounds through mycobacteria membrane; f) ClpP proteins (ClpP1 and ClpP2) – involved in protein turnover [6].

During the last years, potent and selective antitubercular compounds were identified. The compound 6-chloro-2-ethyl-(4-(4-(4-(trifluoromethoxy)phenyl)piperidin-1-yl)benzyl)imidazo [1,2-a] pyridine-3-carboxamide (Q203), for example, acts by inhibition of QcrB of the cytochrome bc1-a3 complex. The MIC₅₀ value against *M. tuberculosis* H37Rv was found to be 2.7 nM. Furthermore, in vivo studies revealed that infected mice treated with Q203 for 4 weeks (at 10 mg/Kg) have reduced the mycobacterial load at 99% in lungs [7]. Another example is the compound ((2R,3S,4R,5R)-5-(6-amino-2-phenyl-9-H-purin-9-yl)-3,4-dihydroxytetrahydrofururan-2-yl)methyl (2-hydroxybenzoyl)sulfamate that demonstrated MIC₅₀ value of 49 nM against *M. tuberculosis* H37Rv under iron deficient conditions. This compound acts by inhibition of aryl acid denylating enzyme (AAAE), known as MbtA, involved in iron metabolism in MTB. The selectivity index using Vero cells was characterized as being superior to 2000 for this chemical structure. Despite the potent in vitro activity this molecule demonstrated inadequate pharmacokinetic profile with low bioavailability and short half-life [8].

During screening using whole-cell assays the compound 1-1-(1-(3R,5R,7R)-adamantan-2-yl)-3-(2,3,4-trifluorophenyl)urea have exhibited MIC value of 30 nM against *M. tuberculosis* (H37Rv) and it also demonstrated activity against MDR strains [9]. Using genetic approach, it was characterized through sequencing of resistant mutants the MmpL3 for this molecule. Afterward, the optimization of pharmacokinetic properties was performed in order to improve the water solubility and reduce the lipophilicility [10]. Another example of target identified after phenotypic assay occurred with the compound 1-(4-(tert-butyl)benzyl)-3-nitro-1H-1,2,4-triazole. Using high-throughput screening (HTS) approach the authors identified for this molecule MIC₅₀ value of 500 nM. They observed that resistant mutants had presented a mutation in dprE1 gene and that the covalent inhibition of DprE was the mode of action for this compound [11].

*Corresponding author: Jean Leandro dos Santos, Faculdade de Ciências Farmacêuticas, UNESP – Univ Estadual Paulista, Araraquara. Rodovia Araraquara-Jaú Km 01 s/n, 14801-902, Araraquara, São Paulo, Brazil, Tel: (+55)-16-33016972; Fax: (+55)-16-33016960; E-mail: santosjl@fcfar.unesp.br

Received: August 21, 2015; Accepted: August 24, 2015; Published: August 28, 2015

Citation: Fernandes GFS, Chin CM, Santos JL (2015) Screening and Identification of New Potential Targets against *Mycobacterium tuberculosis*. Biochem Pharmaco (Los Angel) 4: e178. doi: 10.4173/2167-0501.1000e178

Copyright: © 2015 Fernandes GFS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
In summary, the development of a new platform driven by phenotypic assays, genetic approach and target-based assays seems to be promising to identify new potential targets and compounds active against *Mycobacterium tuberculosis* resistant strains [12,13]. Despite current advances in this field during the last years, challenges involving the discovery of new drugs against latent tuberculosis are still distant perspectives in the therapy.

**Acknowledgments**

Authors are thankful to Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) (Process: 14/02240-1 and 14/24811-0).

**References**

1. Dos Santos JL, Chin CM (2014) Pharmacology of Antitubercular Drugs: Challenges and Advances. Biochem Pharmacol 3: e164.
2. Manjunatha UH, Smith PW (2015) Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening. Bioorg Med Chem 23: 5087-5097.
3. Zumla AI, Gillespie SH, Hoelscher M, Philips PP, Cole ST, et al. (2014) New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect Dis 14: 327-340.
4. Wyatt PG, Gilbert IH, Read KD, Fairlamb AH (2011) Target validation: linking target and chemical properties to desired product profile. Curr Top Med Chem 11: 1275-1283.
5. Cooper CB (2013) Development of Mycobacterium tuberculosis whole cell screening hits as potential antituberculosis agents. J Med Chem 56: 7755-7760.
6. Dos Santos Fernandes GF, Jornada DH, de Souza PC, Chin CM, Pavan FR, et al. (2015) Current Advances in Antitubercular Drug Discovery: Potent Prototypes and New Targets. Curr Med Chem.
7. Pethe K, Bifani P, Jang J, Kang S, Park S, et al. (2013) Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat Med 19: 1157-1160.
8. Neres J, Labello NP, Somu RV, Boshoff H, Wilson DJ, et al. (2008) Inhibition of siderophore biosynthesis in Mycobacterium tuberculosis with nucleoside bisubstrate analogues: structure-activity relationships of the nucleobase domain of 5′-O-[N-(salicyl)sulfamoyl]adenosine. J Med Chem 51: 5348-5370.
9. Brown JR, North EJ, Hundle MJ, Morisseau C, Scarborough JS, et al. (2011) The structure-activity relationship of urea derivatives as anti-tuberculosis agents. Bioorg Med Chem 19: 5585-5595.
10. North EJ, Scherman MS, Bruhn DF, Scarborough JS, Maddox MM, et al. (2013) Design, Synthesis and Anti-Tuberculosis Activity of 1-Adamantyl-3- Heteroaryl Ureas with Improved in Vitro Pharmacokinetic Properties. Bioorganic Med Chem 21: 2587-2599.
11. Stanley SA, Grant SS, Kawate T, lwase N, Shimizu M, et al. (2012) Identification of novel inhibitors of *M. tuberculosis* growth using whole cell based high-throughput screening. ACS Chem Biol 7: 1377-1384.
12. Filippakopoulos P, Knapp S2 (2014) Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov 13: 337-356.
13. Brand M, Measures AM, Wilson BG, Cortopassi WA, Alexander R, et al. (2015) Small molecule inhibitors of bromodomain-acetyl-lysine interactions. ACS Chem Biol 10: 22-39.